Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems

Advertisement

New Enhanced Small Particle (ESP™) Detection Option for Cytek Northern Lights™ and Cytek Aurora™ Systems Expands Capabilities of Small Particle Research

FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) — Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems. With this optional upgrade, these systems show superior sensitivity and resolution of subcellular materials, including extracellular vesicles (EVs), while maintaining high resolution and high parameter capabilities for cell analysis, making them the preferred choice among researchers and clinicians.

Exosomes are the most commonly studied EV, with a market estimated to increase from $227.5 million in 2023 to $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 20281. Researchers studying exosomes, as well as viruses, small bacteria, and nanoparticles, are moving to flow cytometry because of its high throughput and quantitative detection capabilities. Typically, flow cytometers have been unable to detect particles smaller than 500 nm, limiting their use to the study of cells and larger particles. Now, particles as small as 70 nm can be studied label-free on Cytek’s Full Spectrum Profiling™ (FSP™) analyzers, giving researchers the ability to characterize the full emission spectra of small particles. Cytek is now positioned to be a leader in the growing small particle research market.

Advertisement

With Cytek’s new ESP Detection Option, the rapidly growing areas of research conducted on viruses, small bacteria, EVs, nanoparticles, and other subcellular particles for therapy development and biomedical research are being advanced. EVs can be used in various applications such as biomarker development, diagnostic tools and therapeutic development for delivery of drugs.

“Quantitative measurements of individual EVs are critical to progress in the field, and the excellent fluorescence performance of the Cytek Aurora and Northern Lights systems enables us to make sensitive measurements of both EV size and cargo,” noted the Scintillon Research Institute’s John Nolan, Ph.D. “The new ESP Detection Option provides greatly increased light scatter sensitivity, enabling the discrimination of EV sub-populations with distinctive composition and ultra structure that can affect light scattering. These capabilities empower us to better understand the biogenesis of different types of EVs as well as their biological functions toward using these to both detect and treat disease.”

Added Ming Yan, Ph.D., CTO of Cytek Biosciences, “Cytek’s Aurora and Northern Lights systems have helped revolutionize immunology research and single cell analysis. With the introduction of the ESP Detection Option, we are providing new tools to advance small particle biomedical research and further our mission to provide a complete cell analysis solution to our customers. Bringing improved speed and accuracy to the study of extracellular vesicles, cell to cell communication, and cell signaling in many disease and physiological states, we expect to accelerate the pace of discovery, therapy and diagnostic development, and benefit the community.”

The ESP Detection Option on the Cytek Northern Lights and Cytek Aurora systems adds to Cytek’s portfolio of small particle solutions, including the Cytek Amnis® ImageStream®X Mk II imaging flow cytometer, which enables detection of EV production and captures images of EV uptake by cells.

For availability details and more information on Cytek’s new ESP Detection Option on the Cytek Aurora and Northern Lights systems, please visit https://cytekbio.com/pages/esp.

About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS; the flow cytometer and imaging products under the Amnis® and Guava® brands; the Cytek Orion™ reagent cocktail preparation system, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).

Cytek, ESP, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Amnis, Guava and ImageStream are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding Cytek’s business, product plans and strategies; the estimated exosomes market size, growth and CAGR from 2023 through 2028; Cytek’s ability to be a leader in the growing small particle research market; Cytek’s mission to provide a complete cell analysis solution to its customers; and Cytek’s ability to accelerate the pace of discovery, therapy and diagnostic development and benefit the community. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to global economic and market conditions; competition; market acceptance of Cytek’s current and potential products; Cytek’s dependence on certain sole and single source suppliers; Cytek’s ability to manage the growth and complexity of its organization; Cytek’s ability to manage relationships with key customers and suppliers; Cytek’s ability to retain key employees; and Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC and other filings Cytek Biosciences makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
[email protected]

Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
[email protected]


1 Exosome Diagnostics, Therapeutics and Research Tools: Global Markets by BCC Research, May 2024

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.